CAPR
Capricor Therapeutics, Inc. - Common Stock (CAPR)
$06
About Capricor Therapeutics, Inc. - Common Stock (CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$40.37
52 Week Low
$2.96
Market cap
526.7M
Dividend yield
-
Volume
1,578
Avg. volume
6.0M
P/E ratio
-3.70
Capricor Therapeutics, Inc. - Common Stock News
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$40.37
52 Week Low
$2.96
Market cap
526.7M
Dividend yield
-
Volume
1,578
Avg. volume
6.0M
P/E ratio
-3.70